All treatments
Treatment
Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer.
This study looks at a new drug, Onivyde, for people with HER2-negative breast cancer that has spread to the brain. We want to see if Onivyde can shrink these brain tumors and if it's safe to use. It's a key step in finding better treatments.
For: HER2 negative metastatic breast cancer (MBC) with nervous system involvement and measurable metastasesSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
This study is testing a new combination of treatments for advanced pancreatic cancer that hasn't been treated with chemotherapy before. It compares a new drug mix (irinotecan liposome, oxaliplatin, 5-fluorouracil/leucovorin) against a standard treatment (nab-paclitaxel, gemcitabine) to see which helps people live longer.
For: Metastatic Pancreatic AdenocarcinomaSpain